Last reviewed · How we verify
Hypotonic riboflavin
At a glance
| Generic name | Hypotonic riboflavin |
|---|---|
| Also known as | Hypotonic (low salt) riboflavin solution without dextran |
| Sponsor | Region Skane |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Corneal Crosslinking Treatment Study (PHASE4)
- Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial (PHASE3)
- Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin (PHASE3)
- Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns (NA)
- Transepithelial Corneal Cross-linking Using Iontophoresis (NA)
- Hyperopic LASIK With Crosslinking Versus Standard LASIK (NA)
- Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypotonic riboflavin CI brief — competitive landscape report
- Hypotonic riboflavin updates RSS · CI watch RSS
- Region Skane portfolio CI